



10039645 . 050112 7

PATENT

ATTORNEY DOCKET NO. 00398/510002

Certificate of Mailing: Date of Deposit: April 26, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Julie A. Bowen

Printed name of person mailing correspondence

Julie A. Bowen

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alan S. Kopin et al.

Art Unit: 1646

Serial No.: 10/039,645

Examiner:

Filed: October 25, 2001

Customer No.: 21559

Title: CONSTITUTIVELY ACTIVE, HYPERSENSITIVE, AND
NONFUNCTIONAL RECEPTORS AS NOVEL THERAPEUTIC
AGENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, kindly amend the above-referenced application as follows.

In the Specification:

Replace the paragraph beginning at page 12, line 5 and ending at line 7 with the following amended paragraph rewritten in clean form:

Fig 1. is a table of constitutively active Class A G protein-coupled receptors (SEQ ID NOs: 2-75). The mutations that impart constitutive activity to the receptors are indicated.


Replace the paragraph beginning at page 13, line 20 and ending at page 14, line 4 with the following amended paragraph rewritten in clean form:

Fig 13. is an illustration showing a sequence alignment of the human kappa opioid receptor (ork), the rat kappa opioid receptor (orkr), the human mu opioid receptor (orm), the rat mu opioid receptor (ormr), the human delta opioid receptor (ord), the rat type 1A angiotensin II receptor (AT1A), and the human bradykinin receptor (B2)(SEQ ID NOs: 76-82). Also shown is the N residue, which is located 14 amino acids to the amino-terminus of the "DRY" motif (-14).

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 April 2002



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



\\Clark-w2k1\documents\00398\00398.510002 Preliminary Amendment.wpd

VERSION WITH MARKINGS TO SHOW CHANGES

Replace the paragraph beginning at page 12, line 5 and ending at line 7 with the following amended paragraph:

Fig 1. is a table of constitutively active Class A G protein-coupled receptors (SEQ ID NOs: 2-75[70]). The mutations that impart constitutive activity to the receptors are indicated.

Replace the paragraph beginning at page 13, line 20 and ending at page 14, line 4 with the following amended paragraph:

Fig 13. is an illustration showing a sequence alignment of the human kappa opioid receptor (ork), the rat kappa opioid receptor (orkr), the human mu opioid receptor (orm), the rat mu opioid receptor (ormr), the human delta opioid receptor (ord), the rat type 1A angiotensin II receptor (AT1A), and the human bradykinin receptor (B2)(SEQ ID NOs: [71-77] 76-82). Also shown is the N residue, which is located 14 amino acids to the amino-terminus of the "DRY" motif (-14).